Please try another search
For the nine months ended 30 September 2014, Skystar Bio-Pharmaceutical Company revenues increased 20% to $39.4M. Net income increased 6% to $8.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was partially offset by Research and development increase from $418K to $1.2M (expense), General and administrative increase of 20% to $4.5M (expense).
Period Ending: | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 |
---|---|---|---|---|
Total Revenue | 18.35 | 0 | 6.83 | 30.16 |
Gross Profit | 8.76 | 0 | 2.82 | 26.08 |
Operating Income | 5.4 | -13.24 | 1.17 | 15.35 |
Net Income | 4.91 | -61.05 | 0.98 | 11.4 |
Period Ending: | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 |
---|---|---|---|---|
Total Assets | 5386.51 | 134.99 | 1486.51 | |
Total Liabilities | 5252.19 | 24.53 | 977.59 | |
Total Equity | 134.33 | 110.46 | 508.92 |
Period Ending: | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 |
---|---|---|---|---|
Period Length: | 0 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -260.9 | 4.6 | -151.36 | |
Cash From Investing Activities | -726.3 | -0.92 | -0.28 | |
Cash From Financing Activities | 995.6 | -4.91 | 142.32 | |
Net Change in Cash | 8.4 | -1.29 | -9.18 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review